New Agent for Some Drug-resistant Non-small Cell Lung Cancers Discovered

by Rajshri on  December 26, 2009 at 7:44 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
A team of Dana-Farber Cancer Institute scientists has discovered a compound capable of halting a common type of drug-resistant lung cancer thanks to the ability to make, test, and map the atomic structure of new anti-cancer agents.

In a study to be published in the December 24/31 issue of the journal Nature, the researchers report that non-small cell lung cancers that had become invulnerable to the drugs Iressaâ and Tarcevaâ were stymied by a compound designed and formulated in a Dana-Farber lab. The compound, whose basic chemical framework is different from that of other cancer drugs, acts against a protein – known as an epidermal growth factor receptor (EGFR) kinase – that carries a specific structural defect.

"This type of drug discovery, in which an agent is developed for a specific gene or protein target, and then screened against cancer cells as well as in laboratory models, is rare in academic medicine," says the study's senior author Pasi A. Jänne, MD,PhD, of Dana-Farber and Brigham and Women's Hospital (BWH). "This requires contributions from researchers in multiple disciplines and a coordinated approach to planning experiments and sharing results. That we accomplished this is evidence of the contribution academic medical centers can make to the quest for new cancer treatments."

The study also illustrates how rapidly lung cancer research and treatment are advancing. It was less than five years ago that investigators at Dana-Farber and elsewhere traced some non-small cell lung cancers (NSCLCs) to mutations in the EGFR gene and discovered that Iressa and Tarceva slowed such tumors' growth by targeting the abnormal EGFR protein. While the discovery has extended the lives of thousands of NSCLC patients around the world, EGFR blockers are only temporarily effective: after about eight months of treatment, the tumors begin to grow back. And because the drugs target normal EGFR protein as well as abnormal, many patients have severe side effects such as skin rashes and diarrhea.

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Cancer
Complete Medindia Resources
News Categories:  
Sexual Health Center

Cancer Related News

» Cardio-Pulmonary Function can be a Strong Indicator for Survival Chances of Breast Cancer Patients » Post Surgery Will the Tumour Return? New Breast Cancer Test to Predict Exactly
» Scientists Develop Compound That Triggers Cancer Cell Death » Iraqi National Hopes to Find Affordable Treatment for His Cancer in India
» New Technique can Help Doctors Detect Pancreatic Cancer » Colorectal Cancer Risk Factors Probed
» Breast MRI 'Better Than Clinical Approach for Predicting Chemotherapy's Efficiency' » No Need for PSA-Based Screening for Prostate Cancer: Task Force
Read More >>